Somnio is designed for persons suffering from insomnia. Insomnia is characterised by three main symptoms: sleep onset and sleep maintenance difficulties and early morning wakening. However, insomnia is only diagnosed if the patient has one or more of these symptoms at least three times a week for at least one month and the patient energy levels are reduced, or he/she does not feel sufficiently refreshed.
The term insomnia (from Latin: insomnis = sleepless) relates to sleeping problems where sleep is disrupted by early waking, or difficulties falling asleep or in maintaining sleep through the night.
In our western societies, many are bombarded with stimuli into the late hours of the evening and are on call around the clock. So, it hardly comes as a surprise that according to self-reports, about 35% of the adult population in Germany occasionally suffer from sleep problems and about 7-10% meet the diagnostic criteria for clinically significant insomnia. for clinically significant insomnia.
Those affected are at higher risk of developing cardiovascular diseases such as arterial hypertension or arteriosclerosis which can lead to heart attacks and strokes. The development of mental illness such as depression or anxiety disorder are further potential consequences of chronically disrupted sleep.
Too little sleep undermines the immune system and thus increases the risk of infectious diseases. Fatigue during the day also increases the risk of accidents at work or when driving.
There are many different forms of sleep disorder. It is important to distinguish between organic sleep disorders, such as obstructive sleep apnoea or restless legs syndrome and non-organic sleep disorders. The most common of all sleep disorders is non-organic insomnia, for which sleep-onset and sleep-maintenance problems and early morning wakening are the main symptoms.